Scott Gottlieb

Dr. Scott Gottlieb, former FDA commissioner and healthcare executive, weighs in on cancer drug deals, in vivo CAR-T and the new push on psychedelic therapies. Howard Marks, Oaktree co-chairman and veteran investor, tackles private credit stresses, liquidity risks and market psychology. They cover AI, Fed prospects and the clash between regulation and innovation in short, sharp segments.

Eamon Javers, CNBC reporter covering the new 50% tariffs on selected Canadian goods. Jamieson Greer, U.S. Trade Representative explaining upcoming tariff moves, USMCA and trade policy with Canada, Mexico and China. Scott Gottlieb, former FDA commissioner discussing the cyclospora outbreak, testing challenges and tracing sources. They debate tariffs, market fallout, and why cyclospora is hard to track.

Tom Friedman, a Pulitzer Prize-winning journalist, dives into the complexities of U.S. involvement in Venezuela, cautioning against removing Maduro without a solid democratic transition. He emphasizes the need for a legal framework for foreign investment in the country. Joining him is Scott Gottlieb, a former FDA commissioner, who tackles the regulatory challenges in treating rare diseases, highlighting the importance of streamlined processes for breakthroughs in gene therapy. Their insights intertwine global politics and crucial healthcare discussions.

Guests Steve Witkoff, Trump's former top negotiator, discusses the complexities of Middle East peace talks and the delicate balance in Israel-Hamas negotiations. Former FDA commissioner Scott Gottlieb highlights the urgent public health crises, focusing on alarming measles outbreaks and the need to combat vaccine misinformation. They dive into the repercussions of workforce cuts in health agencies and how these changes could affect American health oversight moving forward. Expect a thought-provoking discussion on governance, health, and international diplomacy.

This podcast features Scott Gottlieb, the former FDA Commissioner and current board member for Pfizer, who discusses the vital effects of funding cuts on health research and the innovation pipeline. Additionally, investor Steve Eisman shares his outlook on market risks tied to the Israel-Iran conflict and the potential for a trade war, offering his unique insights on navigating these turbulent times. The discussion also hints at the emerging drama between OpenAI and Microsoft and the public market ambitions of crypto billionaire Justin Sun.

Dan Murphy, CNBC correspondent reporting from Abu Dhabi on energy and Iran negotiations. Dr. Scott Gottlieb, former FDA commissioner and public health expert. They discuss Iran talks and energy market impacts. They explore a hantavirus outbreak, its transmission and clinical risks. They also cover leadership and policy questions at the FDA.

Dr. Scott Gottlieb, former FDA commissioner and public‑health analyst; Brett Schulman, CEO of Cava and restaurant operator; Ed Zitron, tech critic and CEO of Easy Primary Research. They debate Nvidia’s big AI financing and whether it props up the industry. They cover Cava’s sales, food‑safety precautions and pricing choices after outbreaks. They also discuss vaccine policy pressure on states.

Dr. Scott Gottlieb, physician and former FDA commissioner, offers rapid-fire public-health perspective on a new Ebola strain, vaccines, treatments and U.S. risk. Sebastian Mallaby, author and policy scholar, discusses the Pope’s AI encyclical, risks of unregulated models, company strategies and the politics of advanced AI.

Chris Wright, U.S. Secretary of Energy, outlines energy and Strait of Hormuz concerns. Mark Kelly, U.S. Senator and Armed Services member, discusses munitions and defense spending. Scott Gottlieb, physician and former FDA chief, analyzes the Hantavirus situation and agency staffing. Yanti Saripto, Save the Children leader, describes dire humanitarian conditions and aid delivery challenges.

Scott Gottlieb, former FDA commissioner and healthcare expert, and Patrick Boyle, financial commentator and YouTuber, dive into pressing topics. They explore the political implications of vaccine announcements and transparency issues with big pharma, specifically Pfizer. The conversation shifts to the fintech landscape, discussing the risks of debanking practices and regulatory scrutiny. Gottlieb and Boyle also touch on the geopolitical landscape, with insights into the Ukraine conflict and its broader implications for international relations.